Skip to content

Depreciation at other companies

Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Summit Therapeutics logo
Summit TherapeuticsSMMT
Merck & Co. logo
Merck & Co.MRK
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s depreciation?
Immunovant, Inc. (IMVT) reported depreciation of $96K in Q1 2026.
How has Immunovant, Inc.'s depreciation changed year-over-year?
Immunovant, Inc.'s depreciation decreased by 11.9% year-over-year, from $109K to $96K.
What is the long-term trend for Immunovant, Inc.'s depreciation?
Over 4 years (2022 to 2026), Immunovant, Inc.'s depreciation has grown at a 34.2% compound annual growth rate (CAGR), from $126K to $409K.